GlassScriptPhysician profile
Monica Willson
NPI 1477117711
$4,772.48
in general payments reported to CMS, 2019-2025
27 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $272 · 2024: $2,756 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707 · Education: $65.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,707.26 |
| Education | $65.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $697.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $528.97 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $528.79 | 2023-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $469.93 | 2023-2025 | |
| Lilly USA, LLC | $441.24 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $278.68 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $217.43 | 2023-2025 | Tremfya, Spravato |
| Phathom Pharmaceuticals, INC. | $199.12 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $186.31 | 2023-2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $145.03 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.71 | 2023-2025 | Jardiance |
| Dexcom, INC. | $132.35 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $127.21 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $117.74 | 2023-2025 | Shingrix, Arexvy |
| Ars Pharmaceuticals Operations, INC. | $113.62 | 2025 | Neffy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $87.21 | 2024-2025 | Rexulti |
| Insightec,INC | $68.52 | 2024 | Exablate |
| Astellas Pharma US INC | $66.73 | 2024-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $51.61 | 2024 | Trintellix |
| Xeris Pharmaceuticals, INC. | $49.54 | 2024 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $28.85 | 2023-2025 | Ajovy |
| Inspire Medical Systems, INC. | $22.66 | 2025 | Inspire |
| Corcept Therapeutics | $20.04 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $16.24 | 2023 | |
| Esperion Therapeutics, INC. | $13.43 | 2023 | Nexletol |
| Idorsia Pharmaceuticals US INC | $13.43 | 2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $13.37 | 2024 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Willson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.